Abstract
INTRODUCTION Combination chemotherapy is commonly used in the treatment of leukemia. The use of biological response modifiers in combination with chemotherapeutic drugs offers a novel therapeutic combination with increased efficacy and attenuation of toxic side effects. The mechanism of interaction between the various biological modifiers themselves and that of the biological modifiers with chemotherapeutic agents is still not completely clear. Interferon gamma (IFNγ) is one of the biological modifiers which exerts both an antiproliferative and differentiating capacity on leukemic cells and also interacts with antileukemic agents in a synergistic manner. Our review summarizes and evaluates the mode of this interaction on leukemic cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
